Search Results
Showing Results for idiopathic pulmonary fibrosis,
As touchRESPIRATORY approaches 10 years of providing education for busy respiratory specialists, we are looking to the future—and it certainly looks bright!
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Boehringer Ingelheim has announced that its investigational drug, nerandomilast (BI 1015550), has successfully met the primary endpoint in the phase III FIBRONEER™-ILD study. The trial assessed the absolute change from baseline in forced vital capacity (FVC) [mL] at Week 52 compared ...
Although there is limited evidence on the link between interstitial lung disease (ILD) and malnutrition, malnourished patients tend to have shorter survival rates, regardless of disease severity. A late-breaking abstract presented at ERS 2024 titled “Dietetic intervention in malnourished patients with interstitial lung disease (ILD): a pilot trial” investigated whether dietitian involvement could provide meaningful benefits to these patients, potentially laying the groundwork for further research and future clinical guidelines.
Pentraxin-2 is a member of the pentraxin family of proteins, which includes C-reactive protein (CRP), pentraxin-2 and pentraxin-3.1–3 When initially discovered and characterized, pentraxin-2 was known as serum amyloid P (SAP) due to its isolation from amyloid deposits in humans; ...
Interstitial lung diseases (ILDs) are a heterogeneous group of disorders characterized by inflammation and/or fibrosis.1 Pulmonary fibrosis develops due to repeated cycles of injury and impaired repair with fibroblast activation and migration with the resultant deposition of extracellular matrix ...
Chronic cough, defined as a cough lasting over 8 weeks, has an estimated global prevalence of 10% and has significant detrimental physical, social and psychological consequences on individuals.1,2 Chronic cough is a complex heterogeneous disease, in which many causative factors need to ...
Pulmonary alveolar proteinosis (PAP) is a rare pulmonary syndrome with a prevalence of approximately seven cases per 1 million individuals.1,2 PAP affects people of all age, sex, race and socioeconomic status. Based on the largest population studies conducted in the United ...
Idiopathic pulmonary fibrosis (IPF) is a serious chronic lung disease which results in symptoms such as shortness of breath and dry cough and is caused by fibrosis of the lungs. It was a pleasure to talk with Dr. Steven D. ...
The TETON program consists of two currently recruiting phase 3 randomized, double-blind, placebo-controlled studies that are investigating the efficacy and safety of inhaled treprostinil in idiopathic pulmonary fibrosis (NCT04708782, NCT05255991). It was a pleasure to talk with Dr. Steven D. Nathan (...
Interstitial lung disease (ILD) frequently complicates rheumatoid arthritis (RA).1 Moreover, it is more common among those who are male, smoke or are seropositive and with increasing age.1 Emergent risk factors include gain-of-function promoter variants in the MUC5B gene and ...
The Pulmonary Fibrosis Foundation (PFF) Registry is collecting data from patients with pulmonary fibrosis (PF) or interstitial lung disease (ILD), lung transplant recipients who have had PF or ILD as well as caregivers and family members of patients to help ...
The Pulmonary Fibrosis Foundation (PFF) Registry is collecting data from patients with pulmonary fibrosis (PF) or interstitial lung disease (ILD), lung transplant recipients who have had PF or ILD as well as caregivers and family members of patients to help ...
touchRESPIRATORY were delighted to talk with Bill Schmidt, President and CEO of the Pulmonary Fibrosis Foundation (PFF) around the goals of the Pulmonary Fibrosis Awareness Month taking place over September, this year's theme “Here for Each Other” and the importance ...
Pirfenidone is an oral anti-inflammatory and anti-fibrotic drug that was approved for the treatment of idiopathic pulmonary fibrosis (IPF) in 2014. touchRESPIRATORY caught up with Prof. Jürgen Behr (Ludwig-Maximilians-University of Munich, Munich, Germany) to discuss the aims, design, and findings ...
Idiopathic pulmonary fibrosis (IPF) is a rare, progressive lung disease, in which the lungs become scarred making breathing difficult and most patients with IPF progress to advanced disease. It was a pleasure to talk with Prof. Jürgen Behr (Ludwig-Maximilians-University ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
